EP3448852A4 - Nouveaux composés hétérocycliques comme inhibiteurs de la tyrosine kinase bcr-abl - Google Patents

Nouveaux composés hétérocycliques comme inhibiteurs de la tyrosine kinase bcr-abl Download PDF

Info

Publication number
EP3448852A4
EP3448852A4 EP17788800.5A EP17788800A EP3448852A4 EP 3448852 A4 EP3448852 A4 EP 3448852A4 EP 17788800 A EP17788800 A EP 17788800A EP 3448852 A4 EP3448852 A4 EP 3448852A4
Authority
EP
European Patent Office
Prior art keywords
tyrosine kinase
heterocyclic compounds
novel heterocyclic
abl inhibitors
kinase bcr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP17788800.5A
Other languages
German (de)
English (en)
Other versions
EP3448852A1 (fr
Inventor
Lianhai Li
Chunrong Yu
Haihong Huang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Astar Biotech LLC
Original Assignee
Astar Biotech LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astar Biotech LLC filed Critical Astar Biotech LLC
Publication of EP3448852A1 publication Critical patent/EP3448852A1/fr
Publication of EP3448852A4 publication Critical patent/EP3448852A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/56—Amides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
EP17788800.5A 2016-04-29 2017-04-27 Nouveaux composés hétérocycliques comme inhibiteurs de la tyrosine kinase bcr-abl Withdrawn EP3448852A4 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662391402P 2016-04-29 2016-04-29
PCT/CN2017/082243 WO2017186148A1 (fr) 2016-04-29 2017-04-27 Nouveaux composés hétérocycliques comme inhibiteurs de la tyrosine kinase bcr-abl

Publications (2)

Publication Number Publication Date
EP3448852A1 EP3448852A1 (fr) 2019-03-06
EP3448852A4 true EP3448852A4 (fr) 2019-04-10

Family

ID=60161851

Family Applications (1)

Application Number Title Priority Date Filing Date
EP17788800.5A Withdrawn EP3448852A4 (fr) 2016-04-29 2017-04-27 Nouveaux composés hétérocycliques comme inhibiteurs de la tyrosine kinase bcr-abl

Country Status (4)

Country Link
EP (1) EP3448852A4 (fr)
JP (1) JP2019515932A (fr)
CN (1) CN109790144A (fr)
WO (1) WO2017186148A1 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7366031B2 (ja) * 2017-09-22 2023-10-20 カイメラ セラピューティクス， インコーポレイテッド タンパク質分解剤およびそれらの使用
CN115215838B (zh) 2018-09-18 2025-04-04 拓臻股份有限公司 用于治疗特定白血病的化合物
WO2020087202A1 (fr) * 2018-10-29 2020-05-07 Merck Sharp & Dohme Corp. Modulateurs allostériques de 3-(1h-pyrazol-4-yl)pyridine du récepteur muscarinique m4 de l'acétylcholine
WO2021018194A1 (fr) * 2019-07-29 2021-02-04 Ascentage Pharma (Suzhou) Co., Ltd. Composés hétérocycliques utilisés en tant qu'inhibiteurs de bcr-abl
CN113121524B (zh) * 2019-12-31 2023-04-25 南京创济生物医药有限公司 杂环亚砜亚胺化合物及其中间体、制备方法和应用
WO2021143927A1 (fr) * 2020-01-19 2021-07-22 正大天晴药业集团股份有限公司 Composé agissant en tant qu'inhibiteur de bcr-abl
MX2024004025A (es) * 2021-09-30 2024-05-31 Jiangsu Hansoh Pharmaceutical Group Co Ltd Compuesto cíclico fusionado de cuatro miembros y método de preparación y uso de este.
CN116135851B (zh) * 2021-11-17 2025-09-23 武汉众诚康健生物医药科技有限公司 一种芳香胺化合物及其应用
CN120981465A (zh) * 2023-03-30 2025-11-18 江苏豪森药业集团有限公司 四元稠环类化合物盐晶型及其制备方法和应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013171639A1 (fr) * 2012-05-15 2013-11-21 Novartis Ag Composés et compositions pour inhiber l'activité d'abl1, abl2 et bcr-abl1
WO2013171641A1 (fr) * 2012-05-15 2013-11-21 Novartis Ag Composés et compositions pour l'inhibition de l'activité abl1, abl2 et bcr-abl1
WO2013171642A1 (fr) * 2012-05-15 2013-11-21 Novartis Ag Dérivés de benzamide pour inhiber l'activité d'abl1, d'abl2 et de bcr-abl2

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040138269A1 (en) * 2002-10-11 2004-07-15 Sugen, Inc. Substituted pyrroles as kinase inhibitors
WO2004056774A2 (fr) * 2002-12-19 2004-07-08 Neurogen Corporation Analogues d'arylamide d'acide biphenyl-4-carboxylique substitues
AR047894A1 (es) * 2004-02-25 2006-03-01 Wyeth Corp Derivados de tiofeno como inhibidores de la proteina tirosina fosfatasa 1b (ptpasa 1b); metodos para su preparacion, composiciones farmaceuticas que los contienen y su uso en el tratamiento de enfermedades mediadas por ptpasa 1b
US20070054916A1 (en) * 2004-10-01 2007-03-08 Amgen Inc. Aryl nitrogen-containing bicyclic compounds and methods of use
US9278981B2 (en) * 2012-05-15 2016-03-08 Novartis Ag Compounds and compositions for inhibiting the activity of ABL1, ABL2 and BCR-ABL1

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013171639A1 (fr) * 2012-05-15 2013-11-21 Novartis Ag Composés et compositions pour inhiber l'activité d'abl1, abl2 et bcr-abl1
WO2013171641A1 (fr) * 2012-05-15 2013-11-21 Novartis Ag Composés et compositions pour l'inhibition de l'activité abl1, abl2 et bcr-abl1
WO2013171642A1 (fr) * 2012-05-15 2013-11-21 Novartis Ag Dérivés de benzamide pour inhiber l'activité d'abl1, d'abl2 et de bcr-abl2

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO2017186148A1 *

Also Published As

Publication number Publication date
WO2017186148A1 (fr) 2017-11-02
CN109790144A (zh) 2019-05-21
JP2019515932A (ja) 2019-06-13
EP3448852A1 (fr) 2019-03-06

Similar Documents

Publication Publication Date Title
HUS2400003I1 (hu) Kináz inhibitorként alkalmas vegyületek
IL279258B (en) tyrosine kinase inhibitors
IL268614B (en) Aminotriazolopyridines as kinase inhibitors
EP3138842A4 (fr) Composés polyfluorés agissant en tant qu'inhibiteurs de la tyrosine kinase de bruton
EP3166608A4 (fr) Composés aminopyridazinone à utiliser en tant qu'inhibiteurs de protéines kinases
EP3131900A4 (fr) Inhibiteurs de kinase hétérocycliques
EP3297437A4 (fr) Composés hétérocycliques utilisés en tant qu'inhibiteurs de kinases
EP3246328A4 (fr) Composé hétérocyclique quinazoléine comme inhibiteur de l'egfr kinase, son procédé de préparation et son application
IL274207B (en) Aminoimidazopyridazines as kinase inhibitors
MA42242A (fr) Inhibiteurs de la tyrosine kinase
EP3145512A4 (fr) Composés éthynyle hétérobicycliques substitués en tant qu'inhibiteurs de la tyrosine kinase
IL266789A (en) Heterocyclic compounds as kinase inhibitors
EP3294712A4 (fr) Composés hétéroaryle d'inhibition de la kinase
IL304547A (en) 3-substituted benzamide derivatives as kinase inhibitors
IL247867A0 (en) Modified oxazole-diazespiroalkane derivatives as spleen tyrosine kinase inhibitors
AU2024203236A1 (en) Heterocyclic compounds as RET kinase inhibitors
HK40037119A (en) Pyrimidine compounds useful as tyrosine kinase inhibitors
EP3727387A4 (fr) Composés de pyrimidine utiles en tant qu'inhibiteurs de tyrosine kinase
HK40042815A (en) Heterocyclic compounds as kinase inhibitors
AU2017904208A0 (en) Novel kinase inhibitors i
AU2016904206A0 (en) Novel kinase inhibitors i
HK40004305A (en) Kinase inhibitors
HK1233630A1 (en) Diazaspiroalkaneone-substituted oxazole derivatives as spleen tyrosine kinase inhibitors
HK1260208A1 (en) Heterocyclic compounds as ret kinase inhibitors
GB201613945D0 (en) Compounds useful as kinase inhibitors

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20181126

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

A4 Supplementary search report drawn up and despatched

Effective date: 20190314

RIC1 Information provided on ipc code assigned before grant

Ipc: C07D 491/10 20060101ALI20190307BHEP

Ipc: C07D 403/10 20060101ALI20190307BHEP

Ipc: C07D 403/14 20060101ALI20190307BHEP

Ipc: C07D 471/04 20060101ALI20190307BHEP

Ipc: C07D 401/04 20060101ALI20190307BHEP

Ipc: A61P 35/00 20060101ALI20190307BHEP

Ipc: C07D 498/08 20060101ALI20190307BHEP

Ipc: C07D 401/14 20060101AFI20190307BHEP

Ipc: C07D 401/10 20060101ALI20190307BHEP

Ipc: C07D 487/04 20060101ALI20190307BHEP

Ipc: C07D 487/10 20060101ALI20190307BHEP

Ipc: A61K 31/4439 20060101ALI20190307BHEP

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

18W Application withdrawn

Effective date: 20200108